Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open-label, Multicenter Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors

NCT05735366 is registered in ClinicalTrials.gov with Chugai Pharmaceutical as lead sponsor.

NCT NCT05735366
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05735366 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open-label, Multicenter Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Chugai Pharmaceutical
Phase
Phase 1
Overall status
Completed
Start date
April 17, 2023
Completion date
January 26, 2026
Enrollment
22 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor